Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations

  Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial
  Results Exceeded Expectations

Business Wire

NEW YORK & PETACH TIKVAH, Israel -- February 27, 2013

BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem
cell technologies for neurodegenerative diseases, announced that the company
was recently featured on national and local news, as well as Fox News.

Rasheda Ali, a member of BrainStorm’s advisory board and revered author and
daughter of renowned boxer Muhammad Ali, discussed BrainStorm’s promising ALS
clinical trials last week on NBC NY and Current TV’s Viewpoint. She was also
interviewed on Fox News’ Geraldo at Large and Neil Cavuto shows.

In her various interviews, Ms. Ali stated that BrainStorm’s Phase I/II ALS
clinical trial results with its NurOwn™ stem cell candidate exceeded
scientists’ expectations, surpassing the goal of confirming safety by also
showing initial signs of clinical improvement. She also discussed BrainStorm’s
recent acceleration to a Phase IIa trial by the Israeli Ministry of Health.

Ms. Ali’s interviews can be viewed at the following links:

NBC NY: http://bit.ly/Xam0rG.

Current TV Viewpoint: http://bit.ly/13VDZRY

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company holds the rights to develop and commercialize its NurOwn™
technology through an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more information,
visit the company’s website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements.
Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”,
“likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar
terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, risks
associated with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key executives and
on its scientific consultants; ability to obtain required regulatory
approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place undue
reliance on BrainStorm’s forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to
reflect actual results or assumptions if circumstances or management’s
beliefs, expectations or opinions should change, unless otherwise required by
law. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.

Contact:

BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Alon Natanson, CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com
 
Press spacebar to pause and continue. Press esc to stop.